XLO Earnings Date: Nov 12, 2026 (Estimated) — Xilio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is XLO's next earnings date?
Xilio Therapeutics, Inc. (XLO) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.94 on revenue of $4.9M.
How did XLO do in its last earnings report?
In its most recent report on Aug 13, 2026, Xilio Therapeutics, Inc. posted EPS of -$0.33 versus the -$0.59 estimate, a beat of 44.1%. Revenue was $18.7M against a $12.7M estimate. The stock's 1-day post-earnings move was +1.3%.
How much does XLO stock move after earnings?
XLO beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.9% (up or down) in the day after earnings.
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | -0.59 | -0.33 | +44.07% | $18.7M | ✅ Beat | +1.33% | +3.98% | -1.33% | |
| 2026-08-12 | Q2 2026 | -0.59 | -0.33 | +44.07% | $18.7M | ✅ Beat | -1.42% | +3.49% | -2.72% |
| 2026-05-12 | Q1 2026 | -0.66 | -0.58 | +12.12% | $12.6M | ✅ Beat | +0.00% | +5.43% | +2.20% |
| 2026-03-23 | Q4 2025 | -0.74 | 0.81 | +209.46% | $13.7M | ✅ Beat | +0.00% | +5.85% | +8.40% |
| 2025-11-13 | Q3 2025 | -0.03 | -0.11 | -266.67% | $19.1M | ❌ Miss | -9.32% | +4.34% | -11.96% |
| 2025-08-14 | Q2 2025 | -0.08 | -0.16 | -100.00% | $8.1M | ❌ Miss | -1.72% | -7.19% | +3.00% |
| 2025-03-11 | Q4 2024 | -0.24 | -0.20 | +16.67% | $1.7M | ✅ Beat | -6.17% | -4.48% | -23.60% |
| 2024-11-07 | Q3 2024 | -0.25 | -0.22 | +12.00% | $2.3M | ✅ Beat | -19.38% | -22.65% | -15.50% |
Showing last 8 quarters.